secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001213900-23-085197
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics Q3 net loss $2.29M; Toray license cut to 7.5% royalty
-------------------------------------------------------------------------

- Net loss $2.29M ($2.08/share) for Q3 2023; nine-month loss $7.65M ($7.30/share).
- Cash $5.08M as of Sep 30, 2023, down from $10.1M; expects funding into Q1 2024, needs more capital.
- Renegotiated Toray license: royalty reduced from 15% to 7.5% for 10 years; 50% reduction after patent expiry.
- Plans to submit FDA 510(k) for Symphony IL-6 in first half 2024 based on August 2023 feedback.
- Also renegotiated supply agreement with Toray for cartridge component supply for clinical studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390023085197/0001213900-23-085197-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390023085197/ea187862-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-085197

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer